A free research study at Nebraska Medicine is offering you the chance to learn how your genetics could impact your health.

In a preclinical study, UC Davis Comprehensive Cancer Center scientists developed a highly targeted gene therapy that could revolutionize treatment for cancers linked to a common herpesvirus, with ...

Stay informed on key pharmaceutical news, including tariff updates, FDA shutdown risks, and insights from recent cell and ...

While AMT-130 could result in meaningful revenue for ClearPoint, the Huntington's opportunity is relatively modest compared ...

Universities must do more to provide students with cell and gene therapy manufacturing skills, according to a new study.

Taysha Gene Therapies stock surges after FDA alignment on a pivotal Rett Syndrome study. Read the latest analysis on TSHA ...

CSL Behring in King of Prussia is behind HEMGENIX, the first FDA-approved gene therapy transforming life for hemophilia ...

Cirrus Therapeutics secured an $11 million seed financing led by ClavystBio. Polaris Partners and SEEDS also joined in the ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.33, a high estimate of ...

Taysha also announced that it has finalized alignment with the FDA on the protocol for the trial intended to support its ...

As September concludes, the landscape of hematologic oncology continues to evolve, spanning the full spectrum of blood cancer ...

University of Bristol biotech spin-out company Cirrus Therapeutics has today (Thursday 2 October) announced the close of an ...